Update on antifungals targeted to the cell wall: focus on beta-1,3-glucan synthase inhibitors.
about
Overexpression of Sbe2p, a Golgi protein, results in resistance to caspofungin in Saccharomyces cerevisiae.Importance of microbial natural products and the need to revitalize their discovery.Inhibition of fungal beta-1,3-glucan synthase and cell growth by HM-1 killer toxin single-chain anti-idiotypic antibodies.Discovery of Short Peptides Exhibiting High Potency against Cryptococcus neoformansPopulation genomics of drug resistance in Candida albicans.Antifungal efficacy of caspofungin (MK-0991) in experimental pulmonary aspergillosis in persistently neutropenic rabbits: pharmacokinetics, drug disposition, and relationship to galactomannan antigenemia.Comparative antifungal activities and plasma pharmacokinetics of micafungin (FK463) against disseminated candidiasis and invasive pulmonary aspergillosis in persistently neutropenic rabbits.Effect of the echinocandin caspofungin on expression of Candida albicans secretory aspartyl proteinases and phospholipase in vitroMicafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation.Invasive candidiasis in critical care setting, updated recommendations from "Invasive Fungal Infections-Clinical Forum", Iran.Fungal biofilms and drug resistance.Antifungals targeted to protein modification: focus on protein N-myristoyltransferase.Efficacy of micafungin alone or in combination against systemic murine aspergillosis.Antifungal pharmacotherapy for invasive mould infections.Efficacy of ambruticin analogs in a murine model of coccidioidomycosis.Caspofungin: first approved agent in a new class of antifungals.The Cryptococcus neoformans MAP kinase Mpk1 regulates cell integrity in response to antifungal drugs and loss of calcineurin functionPharmacodynamics of echinocandins against Candida glabrata: requirement for dosage escalation to achieve maximal antifungal activity in neutropenic hostsAn assessment of growth media enrichment on lipid metabolome and the concurrent phenotypic properties of Candida albicansAnidulafungin: an echinocandin antifungal.High cumulative dose exposure to voriconazole is associated with cutaneous squamous cell carcinoma in lung transplant recipients.Pharmacological properties and clinical efficacy of a recently licensed systemic antifungal, caspofungin.Characterization of caspofungin susceptibilities by broth and agar in Candida albicans clinical isolates with characterized mechanisms of azole resistanceCombination therapy in treatment of experimental pulmonary aspergillosis: in vitro and in vivo correlations of the concentration- and dose- dependent interactions between anidulafungin and voriconazole by Bliss independence drug interaction analysisMicrobial drug discovery: 80 years of progress.Biofilm formation and effect of caspofungin on biofilm structure of Candida species bloodstream isolatesChitinases are essential for sexual development but not vegetative growth in Cryptococcus neoformans.Invasive fungal infections in the ICU.A clinical review of echinocandins in pediatric patients.Antifungal Therapy for Systemic Mycosis and the Nanobiotechnology Era: Improving Efficacy, Biodistribution and Toxicity.Caspofungin therapy in immunocompromised children and neonates.Antimicrobial peptides: to membranes and beyond.Invasive fungal infections in the ICU: how to approach, how to treat.Investigation of the efficacy of micafungin in the treatment of histoplasmosis using two North American strains of Histoplasma capsulatum.Antifungal Activity of Eucalyptus Oil against Rice Blast Fungi and the Possible Mechanism of Gene Expression Pattern.Comparative evaluation of disk diffusion with microdilution assay in susceptibility testing of caspofungin against Aspergillus and Fusarium isolatesBgs3p, a putative 1,3-beta-glucan synthase subunit, is required for cell wall assembly in Schizosaccharomyces pombeAntifungal spectrum, in vivo efficacy, and structure-activity relationship of ilicicolin h.In vitro antifungal activity of Micafungin (FK463) against dimorphic fungi: comparison of yeast-like and mycelial forms.Comparison of two methods and three end points in determination of in vitro activity of micafungin against Aspergillus spp.
P2860
Q30837205-F9CD283D-9F3C-42DB-9C31-7B42ACD5A1CBQ31128037-1D91885E-9F6D-4ACB-AC1A-A9EFEED75580Q33255739-655B5DD2-5C59-4018-A1BB-BC0603E12F46Q33636123-2F64C4FD-B068-4323-A49A-BC09D39ABC18Q34034817-C9058360-0C32-4D27-9482-A86ADD864EF3Q34104748-3702C9B9-F724-4098-8912-1F0BFE0C0A62Q34108880-2E8B8E46-CE8B-49FE-AF43-943E79E4FE6FQ34112321-26311447-99CF-47E5-8F0B-5FBDEF8E4BE6Q34368144-FCD0CCFB-4BB9-4CC6-BADE-0BCE280C3D3AQ34452343-42BCA051-DD0E-4AAF-8A04-B88DA231E783Q34540389-E5BECB4D-9452-44C8-80FF-FB77A9F3310CQ34768569-200A583D-38D6-4632-83CD-ED89CF52BA01Q34884594-84C660CA-5952-4738-A83A-8FDA116E717EQ35058091-5C13A59C-6A56-4839-8B09-53C14BAE1339Q35091499-650462BD-CE2D-4278-9B32-92A85D3235FAQ35124726-CA80557A-F587-45D2-ABD3-E7F99992854AQ35128586-F733CF72-989B-4DF8-8B4A-EDAA5289CE84Q35270758-2E61C933-2820-47BA-BDEA-03C840EC2479Q35448907-6EA4DF99-C313-4634-9070-D7F1EE130294Q35871936-06A5D966-1426-4CD2-AEA3-101B7FDF7E6CQ36019684-2BC91EE2-E62C-46B8-8E6F-2A55674304B8Q36176371-BC005787-A1C4-45F8-9A91-B6147CFDED29Q36925967-F6421466-FF15-4A20-91A6-572BEFF265ABQ37204192-104B907C-F2F2-48F0-8D04-440478D45AFEQ37365189-00710162-243B-40E9-8ED9-A16704B8ABE0Q37392907-2BD51C17-F989-48C5-961D-6CB1C5DF4293Q37410090-5C60050A-4193-4CA7-A672-FE42FFF1D54DQ37643057-F36E846D-2EFB-472D-9CA7-1BCB8EDCD2F8Q37653647-D1C94F82-8F3D-4B7F-84CF-1B564BA8B2BFQ37684378-E761C0F6-5A9A-48B3-BF86-B4CC84D45666Q37854725-A8ADBD91-6849-4757-9084-F2B52EDCCB9AQ38089201-FB738D49-D0A4-4B0F-B0F2-19BEB68D7148Q38180287-BA5F3F8B-1ACE-4850-A86E-5896D2924ADCQ38282677-09B783E9-D498-4C36-A27E-914FDF88472AQ38447267-EE276D1D-9F97-46F1-B2EE-FE96B85FABC2Q39652840-DE7904F0-4DBC-4267-9516-86C8991BD5A7Q39700598-BB662F8A-4CC9-43C1-A5CD-8BEB382C9BABQ39733057-31521189-736F-40C9-9816-46F89460842CQ39743508-3BF04866-F7F1-4CB7-A1B6-6FB1026ED641Q39792671-F39EF91D-8623-4226-A293-41F62F121B81
P2860
Update on antifungals targeted to the cell wall: focus on beta-1,3-glucan synthase inhibitors.
description
2001 nî lūn-bûn
@nan
2001 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Update on antifungals targeted ...... ,3-glucan synthase inhibitors.
@ast
Update on antifungals targeted ...... ,3-glucan synthase inhibitors.
@en
type
label
Update on antifungals targeted ...... ,3-glucan synthase inhibitors.
@ast
Update on antifungals targeted ...... ,3-glucan synthase inhibitors.
@en
prefLabel
Update on antifungals targeted ...... ,3-glucan synthase inhibitors.
@ast
Update on antifungals targeted ...... ,3-glucan synthase inhibitors.
@en
P2860
P1476
Update on antifungals targeted ...... ,3-glucan synthase inhibitors.
@en
P2093
Georgopapadakou NH
P2860
P304
P356
10.1517/13543784.10.2.269
P407
P577
2001-02-01T00:00:00Z